Lumasiran
Brand names: Oxlumo
Lumasiran is a subcutaneous small interfering RNA (siRNA) therapy used to treat primary hyperoxaluria type 1 in adults and children.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is an RNA interference agent that reduces hepatic glycolate oxidase by degrading its messenger RNA, lowering the production of oxalate and thereby reducing urinary and plasma oxalate.
Prescribing in practice
- Treatment should be initiated and supervised by specialists experienced in managing primary hyperoxaluria, with monitoring of oxalate response.
- Injection-site reactions are among the most frequently reported adverse effects.
- Dosing in children is by body weight and should follow specialist protocols and a children's formulary.
Monitoring
Monitor urinary and/or plasma oxalate to assess response to treatment under specialist supervision.
Counselling the patient
- This medicine is given as an injection under the skin, usually by a healthcare professional.
- Maintaining good fluid intake remains important alongside this treatment.
- Report marked or persistent injection-site reactions.
Evidence & guidelines
Lumasiran is licensed for primary hyperoxaluria type 1, with the ILLUMINATE trials showing substantial reductions in urinary oxalate versus placebo.
Reference: NICE HST; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).